Clinical Trial Update: A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia [Phase 1, Phase 2]

View source ↗

Summary

Design Therapeutics is conducting a multiple ascending dose study of DT-216P2 in patients with Friedreich's ataxia. The trial is a Phase 1/2 study and is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• DT-216P2

Snippet

Sponsor: Design Therapeutics, Inc. | Conditions: Friedreich Ataxia | Phase 1, Phase 2 | Status: RECRUITING